Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. (Record no. 22137776)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 01641 a2200397 4500 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20250516113203.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 201304s 0 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1557-3265 |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1158/1078-0432.CCR-12-0178 |
Source of number or code | doi |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | NLM |
Language of cataloging | eng |
Transcribing agency | NLM |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Janku, Filip |
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Date of production, publication, distribution, manufacture, or copyright notice | 20130426 |
245 00 - TITLE STATEMENT | |
Title | Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. |
Medium | [electronic resource] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Name of publisher, distributor, etc. | Clinical cancer research : an official journal of the American Association for Cancer Research |
Date of publication, distribution, etc. | Nov 2012 |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 6356-63 p. |
Other physical details | digital |
500 ## - GENERAL NOTE | |
General note | Publication Type: Journal Article; Research Support, N.I.H., Extramural |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Antineoplastic Agents |
General subdivision | therapeutic use |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Carcinoma, Non-Small-Cell Lung |
General subdivision | drug therapy |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Clinical Trials, Phase II as Topic |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Disease-Free Survival |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Gefitinib |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Humans |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Lung Neoplasms |
General subdivision | drug therapy |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Molecular Targeted Therapy |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Multicenter Studies as Topic |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Multivariate Analysis |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Quinazolines |
General subdivision | therapeutic use |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Treatment Outcome |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Berry, Donald A |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Gong, Jing |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Parsons, Henrique A |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Stewart, David J |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Kurzrock, Razelle |
773 0# - HOST ITEM ENTRY | |
Title | Clinical cancer research : an official journal of the American Association for Cancer Research |
Related parts | vol. 18 |
-- | no. 22 |
-- | p. 6356-63 |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://doi.org/10.1158/1078-0432.CCR-12-0178">https://doi.org/10.1158/1078-0432.CCR-12-0178</a> |
Public note | Available from publisher's website |
No items available.